Events

September 20

iCAN science seminar: Dr. Daniel Hodson

Deciphering the Genomics of Aggressive Lymphomas
Speaker: Dr. Daniel Hodson, MD, PhD
Host: Prof. Sirpa Leppä

Minibio:

Dr Hodson studied medicine at Cambridge and Oxford Universities before training in clinical haematology in Cambridge. He undertook a University of Cambridge PhD in molecular immunology supervised by Dr Martin Turner at the Babraham Institute. In 2010 he moved as a Kay Kendall Leukaemia Fund (KKLF) Post-doctoral Fellow to the lab of Dr Louis Staudt at the National Cancer Institute, NIH, USA to study the functional genomics of aggressive B cell lymphoma. In 2015 he was awarded a Medical Research Council (MRC) Clinician Scientist Fellowship and returned to Cambridge to establish a research group in the Welcome MRC Cambridge Stem Cell Institute, University of Cambridge. In 2021 he was awarded a Cancer Research UK Senior Research Fellowship and in 2023 a European Research Council Consolidator award.

The Hodson Group researches the molecular mechanisms that underlie lymphomagenesis with a view to identifying new targets for designer anti-lymphoma therapies. Key themes in his lab are molecular profiling (especially ctDNA) to resolve genetic heterogeneity of DLBCL, novel approaches to model the functional genetics of lymphoma, and the mechanistic contribution of RNA helicases in lymphomagenesis. Dr Hodson is also a practising clinician and an honorary Haematology consultant. He runs an active portfolio of clinical trials to study the effect of novel therapies in patients with lymphoma and chairs the UK NCRI Lymphoma Translational Science Subgroup.


Start time: 20/09/2024 09:00
End time: 20/09/2024 10:00
Duration:
Location: Biomedicum Helsinki 1, meeting room Skutsi
Type: Seminar
Organization: iCAN Flagship Team
Contact person: ican-comms@helsinki.fi
September 20

Seminar by Associate Professor Yoshifumi Itoh

MT1-MMP: A cell surface metalloproteinase that modulates cellular microenvironment

Short biography:

After receiving his Msc in Pharmaceutical Sciences from Tokyo College of Pharmacy in Japan, in 1991 Dr Itoh moved to the University of Kansas Medical Center, USA to work with Prof Hideaki Nagase.

 

Using his research outcomes, he received a PhD from the Tokyo University of Pharmacy and Life Sciences, Japan, in 1996. In 1997 he became an Assistant Professor in Prof Motoharu Seiki's department at the Institute of Medical Sciences, University of Tokyo.

 

In 2001 he then moved to the Kennedy Institute of Rheumatology, Imperial College London to run his own lab and relocated to Oxford when the Kennedy Institute joined the University of Oxford.

 

His major scientific interests have been centered on mechanisms of cellular invasion and tissue destruction, especially in the aspects of arthritis and cancer, as they share common mechanisms and pathways.

 

Selected publications

1.   Itoh Y (2022) Proteolytic modulation of tumor microenvironment signals during cancer progression. Front Oncol, 12, 935231

2.   Gifford V, Woskowicz A, Ito N, Balint S, Lagerholm BC, Dustin ML, Itoh Y (2022) Coordination of two kinesin superfamily motor proteins, KIF3A and KIF13A, is essential for pericellular matrix degradation by membrane-type 1 matrix metalloproteinase (MT1-MMP) in cancer cells. Matrix Biology, 107, 1-23. 

3.   Itoh Y, Ng M, Wiberg A, Inoue K, Hirata N, Paiva KBS, Ito N, Dzobo K, Sato N, Gifford V, Fujita Y, Inada M, and Furniss D, (2021) A common SNP risk variant MT1-MMP causative for Dupuytren's Disease has a specific defect in collagenolytic activity. Matrix Biol, 97, 20-39.

4.   Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A and Itoh Y (2016) Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of inflammatory arthritis: synergy with TNF blockade. Arthritis Rheum 68 (2), 521-531 

5.   Woskowicz AM, Weaver SA, Shitomi Y, Ito N, Itoh Y. (2013) MT-LOOP-dependent localization of MT1-MMP to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem. 288, 35126-37.



Start time: 20/09/2024 10:00
End time: 20/09/2024 11:00
Duration: 1 hour
Location: Biomedicum 1, seminar room 3
Type: Seminar
Organization: UH, Faculty of Medicine
Contact person: paivi.ojala@helsinki.fi
September 20

Kliinisen mikrobiologian perjantaisarja

Jätevesien mikrobianalytiikka avaa uusia mahdollisuuksia tartuntatautien seurantaan väestötasolla
Tarja Pitkänen, johtava asiantuntija, Vesimikrobiologian laboratorio THL ja apulaisprofessori
Helsingin yliopiston eläinlääketieteellinen tiedekunta  

Start time: 20/09/2024 12:00
End time: 20/09/2024 13:00
Duration:
Location: HUSLAB talo, 4 krs, Jälki G4101
Type: Seminar
Organization: HUS
Contact person: juulia.suominen@hus.fi
September 20

Dissertation: Eliisa Nissilä

Eliisa Nissilä, University of Helsinki, Faculty of Medicine
Premorbid hazardous alcohol consumption in critically ill patients

Opponent: professor Janne Liisanantti, University of Oulu



Start time: 20/09/2024 12:00
End time: 20/09/2024 12:00
Duration:
Location: HUS Puistosairaala, Niilo Hallman sali, Stenbäckinkatu 11
Type: Dissertation
Organization: UH, Faculty of Medicine
Contact person: eliisa.nissila@hus.fi
September 20

Dissertation: Leo Meriranta

Leo Meriranta, University of Helsinki, Faculty of Medicine
Molecular cross-section of high-risk diffuse large B-cell lymphoma

Opponent: doctor Daniel Hodson, University of Cambridge


Start time: 20/09/2024 12:00
End time: 20/09/2024 14:00
Duration: 2 hours
Location: Naistenklinikka, Seth Wichmann -sali, Haartmaninkatu 2
Type: Dissertation
Organization: UH, Faculty of Medicine
Contact person: leo.meriranta@helsinki.fi